Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Opyl Limited is an Australian clinical trial technology company providing AI-driven patient recruitment and trial optimization platforms for pharmaceutical and biotech sponsors. The company operates ShareMyHealth (patient engagement platform) and TrialKey (predictive analytics for trial design), targeting the $50B+ global clinical trial market. Currently pre-revenue with negative operating margins, the stock trades on technology validation milestones and partnership announcements rather than financial performance.
Opyl targets pharmaceutical and biotech companies seeking to reduce clinical trial costs (average $2.6B per drug approval) and timelines. The business model centers on subscription-based access to AI platforms that predict trial outcomes and accelerate patient enrollment. Pricing power depends on demonstrating measurable ROI through faster recruitment and lower screen failure rates. Competitive advantage lies in proprietary datasets linking patient phenotypes to trial success, though the company faces competition from established CROs (IQVIA, Syneos) and emerging digital health platforms. Current negative gross margins (-352%) reflect R&D-stage operations with minimal revenue against ongoing platform development costs.
Partnership announcements with pharmaceutical companies or CROs for platform pilots or commercial deployments
Clinical validation data showing measurable improvements in trial recruitment speed or patient retention rates
Regulatory approvals or certifications for data handling (HIPAA, GDPR compliance) enabling geographic expansion
Capital raises or funding announcements given negative cash flow and 0.77 current ratio indicating liquidity constraints
Technology milestone achievements such as AI model accuracy improvements or new predictive capabilities
Regulatory risk around patient data privacy and AI/ML algorithm validation requirements by FDA, EMA, and TGA, which could mandate costly clinical evidence before commercial adoption
Technology obsolescence risk as large CROs (IQVIA, Parexel) and tech giants (Google Health, Microsoft) develop competing AI-driven trial platforms with greater resources and established pharma relationships
Market adoption risk given pharmaceutical industry's conservative approach to new technologies and preference for proven CRO relationships over unvalidated software platforms
Competition from established clinical research organizations with existing pharma contracts, site networks, and patient databases that can bundle trial optimization into full-service offerings
Emerging digital health platforms (Science 37, Medable) offering decentralized trial capabilities that may provide superior patient recruitment without requiring separate analytics tools
Low barriers to entry for AI/ML development allowing well-funded startups or pharma in-house teams to replicate predictive analytics capabilities
Critical liquidity risk with 0.77 current ratio and negative operating cash flow of approximately $3.5M annually, suggesting potential capital raise requirement within 6-12 months
Equity dilution risk from future fundraising given pre-revenue status and extended path to profitability, likely requiring multiple financing rounds
Working capital constraints limiting ability to invest in sales infrastructure or platform enhancements needed to convert pilots into commercial contracts
moderate - Clinical trial spending by pharmaceutical companies shows relative resilience during downturns as drug development timelines span 7-10 years and regulatory milestones drive investment decisions more than GDP growth. However, biotech funding (venture capital and IPO markets) is highly cyclical, affecting customer budgets for trial optimization tools. Economic weakness can delay non-critical trials or shift spending toward late-stage assets with clearer commercialization paths.
Rising interest rates negatively impact Opyl through multiple channels: (1) Higher discount rates compress valuations of pre-revenue growth companies with distant profitability, (2) Tighter financial conditions reduce biotech sector funding, shrinking the addressable customer base, (3) Increased cost of capital makes R&D investments less attractive for pharmaceutical sponsors, potentially delaying trial initiations. The company's negative cash flow profile makes it particularly vulnerable to valuation multiple compression in rising rate environments.
Moderate - While Opyl has zero debt (0.00 D/E ratio), the business depends on customer creditworthiness as pharmaceutical and biotech clients face their own financing constraints. Tightening credit conditions reduce biotech IPO activity and venture funding, directly impacting demand for trial optimization services. The company's 0.77 current ratio suggests potential need for external financing, making equity market conditions critical for operational continuity.
growth/speculative - Attracts early-stage technology investors willing to accept binary outcomes and extended timelines to profitability. The stock appeals to thematic healthcare technology investors betting on AI disruption of clinical trials, rather than value or income-focused portfolios. Given pre-revenue status and -787% net margin, investment thesis centers entirely on platform validation and market adoption potential rather than current financial performance. Requires high risk tolerance and 3-5 year investment horizon.
high - Micro-cap stock with minimal revenue exhibits extreme volatility driven by binary news events (partnership announcements, funding rounds, technology milestones). The 37.5% one-year return masks significant intra-period drawdowns, with 6-month return of -33.3% indicating sharp reversals. Low trading liquidity amplifies price swings on modest volume. Beta likely exceeds 1.5 relative to broader healthcare technology indices.
